Treatment of severe infections: Principles of therapy and problems of resistance;Súlyos infekciók antimikrobás kezelése: Terápiás elvek és rezisztenciagondok

Lege Artis Medicinae

Volumn 19, Issue 11, 2009, Pages 665-671

  Ludwig, Endre ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

ESBL producing Gram negatives; MRSA; New antibiotics; Principles of antibiotic treatment; Severe infections

Indexed keywords

EID: 72749098845     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MN, Jaeschke R, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36, 296-327.
2. Valles J, Rello J, Ochagavia A, Garnacho J, Alcula MA, et al. Community acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate therapy on survival. Chest 2003;123:16152005-24.
3. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:1462005-55.
4. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31: S131-8.
5. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:36402005-5.
6. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment fort ventillator-associated pneumonia. Chest 2002;122:2622005-8.
7. Kumar A, Robert D, Wood KE, et al. Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;49:36402005-45.
8. Rello J, Bodi M, Mariscal D, Navarro M, Diaz E, Gallego M, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003;123:1742005-80.
9. Chastre J, Woffl M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventillatorassociated pneumonia in adults: a randomized trial. JAMA 2003;290:25882005-98.
10. Országos Epidemiológiai Központ Honlap, www.oek.hu.
11. Lodise TP, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin susceptible Staphylococcus aureus. Antimicrob Agent Chemother 2007;51:37312005-3.
12. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Inf Dis 2003;36:1418-23.
13. Rybak MJ, Lomeastro BM, Rotschafer JC, Moellering RC, Craig WA, Billetes M, et al. Vancomycin Therapeutic Guidelines: A summary of consensus recommendations from the Infectious Disease Society of America, the American Society of Healthsystem Pharmacist, and the Society of Infectious Diseases Pharmacists. Clin Inf Dis 2009;49:3252005-7.
14. Lodise TP, Craves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:33152005-20.
15. Gemmel CG, Edwards DI, Fraise AP. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006;57:5892005-608.
16. Ingram PR, iye DC, Tamyah PA, Goh WP, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008;62:1682005-71.
17. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in nonvancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007;60:7882005-94.
18. MRSA Referencia Laboratórium ajánlása, Mikrobiológiai Körlevél 2009, 1. szám.
19. Garau J, Bouza E, Chatsre J, Gudiol F, Harbarth S. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 2009;15:1252005-36.
20. Gould FK, Brindle R, Chadwick PR, Fraise AP, Hill S, Nathwani D, et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother. Doi.10.1093/jac/dkp065
21. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007;51:19872005-94.
22. Paterson DL, Ko W, Gottberg A, Mohapatra S, Casellas AJ, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia. Implications of production of extended-spectrum beta-lactamases. Clin Inf Dis 2003;39:312005-7.
23. Noskin GA. Tigecycline: a new glicylcycline for treatment of serious infections. Clin Inf Dis 2005; 41 (Suppl5) : S303-14.
24. Falagas MF, Ilias IS, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam treatment of Gram-positive bacterial infections: metaanalysis of randomised controlled trials. iancet Infectious Diseases 2008;8:532005-64.
25. Livermore DM. Future directions with daptomycin. J Antimicrob Chemother 2008; 62 (Supple3) : iii41-iii49.